SELECT * FROM sessions where years='2017' and sequence=124
December 4-8, 2017 at Atlantic City, New Jersey
The 73rd Deming Conference on Applied Statistics
Sponsored by Metropolitan Section, ASQ and Biopharmaceutical Section, ASA
   
biosketch
      

Back to Program


Statistical & Strategic Considerations in Development of Oncology Immunotherapies

Speaker(s): Dr. Cong Chen, Merk & Co.
Moderator: Naitee Ting
 

Dr. Cong Chen is Director of Early Oncology Biostatistics at Merck & Co., Inc. He joined Merck in 1999 shortly before he graduated from Iowa State University, Ames, USA, with a Ph.D. in statistics. He has published over 60 papers and 6 book chapters on statistical methodologies for design and analysis of clinical trials, including new paradigms for biomarker directed clinical development and Phase II proof-of-concept studies. His most recent accomplishment includes playing a pivotal role in regulatory approval of KEYTRUDA, a paradigm changing anti-PD-1 immunotherapy, for multiple indications. He is a Fellow of American Statistical Association, an Associate Editor of Statistics in Biopharmaceutical Research, a member of Cancer Clinical Research Editorial Board and a co-leader of the DIA Small Population Work Stream.


Back to Program